The Oscar Lambret Center is a national reference center for clinical cancer research.
It is the only cancer center in France’s northernmost region Hauts-de-France.
To implement its research policy, in May 2016 the Direction of Clinical Research and Innovation was created, grouping together the existing components to implement and promote this clinical research activity: the Investigation Department with an integrated care unit (including the certified early phase center), Sponsorship Department (Methodology and Biostatistics Unit and Technical and Regulatory Project Management Unit) and Partnerships and Promotion Department.
Clinical research includes any study that aims to evaluate a new treatment/diagnostic tool or understand the causes or factors influencing the course of the disease. It provides new scientific knowledge necessary to make medical progress and improve care.
Although 80% of clinical trials are to evaluate new drugs, the Center is also very involved in trials investigating new radiotherapy and surgery techniques and trials evaluating quality of life (adapted physical activity, dietetics, humanities and social sciences, etc.).
The Investigation Department, a team working hard to give patients access to the latest innovations
This multidisciplinary department is responsible for patients enrolled in clinical trials at the Oscar Lambret Center.
With over 170 clinical trials each year, including around 30 sponsored by the Center, some 1,000 patients benefit from clinical research at the Center every year, which is above the Cancer Plan target of 10%. This shows just how involved and motivated the Center is when it comes to research and therapeutic innovation.
In 2021, this number increased to 1,309, i.e. 18.6% of patients treated.
The trials conducted at the Oscar Lambret Center are sponsored by the pharmaceutical industry, cooperative and academic groups, but also include research with institutional sponsors.
This Investigation Department has the capacity and motivation to conduct trials in all phases proposed by sponsors in France, Europe and elsewhere, including early phase trials through Lille’s CLIP².